Hamed Hemati Chahardeh has founded PooyaGene Biotech co., 2008 in Iran -at the age of 24 years while holding B.Sc in Genetics- focusing on molecular diagnostic research and manufacturing. Later, he established its branch in India. He has achieved several national awards such as national young entrepreneurship award. He is working as CEO of PooyaGene Biotech Company. He has completed his M.Sc. in Biotechnology and is doing Ph.D. in medical Biotechnology research area. He is already working on his projects in the Department of Biotechnology, Panjab University, India and ILBS-NIH laboratory, Institute of Liver and Biliary Sciences, India.


Hepatocellular Carcinoma (HCC) has a poor prognosis and late stage diagnosis. Therefore, HCC biomarkers are useful in assisting early diagnosis and could have clinical prognostic utility as well. Identification and characterization of liver cancer stem cells (CSCs) promises to have impact on the development of novel diagnostic, prognostic and therapeutic approaches. On the other hand, several oncogenic and tumor suppressive microRNAs (miRNAs) have been validated as biomarkers and possible therapeutic targets in HCC. Additionally, it is already known that cancer stem cells have aberrant levels of specific miRNAs, which results in dysregulation of CSCs properties through the signaling pathways and consequently implicated in tumorigenesis. Based on these facts, in this study we aim to combine promising potential of both cancer stem cells and microRNAs to reveal their diagnostic, prognostic and therapeutic potential. We explore role of microRNAs in pivotal signaling pathways such as Notch, Hedgehog, Wnt/β-catenin, HMGA2, Bcl-2, and Bmi-1, involving in the regulation of self-renewal, differentiation, and survival of liver cancer stem cells. Results indicate that targeting single molecule or particular pathway may have a limited benefit in diagnosis and treatment. Employing biomarkers combinations may be needed to overcome the complex network of signaling pathways.